Morphological manifestations of the immunomodulatory effect of resveratrol in postmenopausal osteoporosis
EDN: PSCAGP
Abstract
Objective - the research of morphological changes in bone marrow, thymus, and spleen in experimental postmenopausal osteoporosis and its treatment with resveratrol.
Material and methods. The study was performed on 15 female Wistar rats. A model of postmenopausal osteoporosis was created by bilateral ovariectomy with a follow-up period of 28 days. Resveratrol therapy in the experimental group was administered daily intraperitoneally at a dose of 2 mg/kg for the same period of observation. Histological and densitometric examinations of the proximal femur, as well as histological and immunohistochemical examinations of the thymus and spleen with computer image analysis and morphometry, were performed.
Results. Bilateral ovariectomy in experimental animals, Wistar rats, 4 weeks after ovariectomy, together with osteoporotic lesions, leads to increased proliferation of cortical thymocytes, accompanied by activation of the reticuloepithelial microenvironment, increased migration of activated (CD45RO+) thymocytes to the spleen, and activation of B-lymphocytopoiesis in the bone marrow and spleen. Resveratrol therapy reduces the severity of morphological manifestations of T- and B-cell activation in the immune system.
Conclusion. In experimental animals, Wistar rats, hypoestrogenism for 4 weeks caused morphological changes in the bone marrow, thymus, and spleen, indicating T- and B-cell activation in the immune system. Resveratrol therapy during the period of estrogen deprivation, along with its osteoprotective and osteoreparative effects, has a negative modulatory effect on immune structures, which may be one of the ways to reduce the osteoreзорбтивной activity of osteoclasts.
About the Authors
Alexander A. Dolzhikov
Belgorod State National Research University (NRU "BelSU")
Russian Federation
Russian Federation
Olga A. Shevchenko
Belgorod State National Research University (NRU "BelSU")
Russian Federation
Russian Federation
Assistant at the Department of Microbiology and Virology with a course in Clinical Immunology, NRU "Bel-SU", Belgorod, Russian Federation
References
1. Arron J.R, Choi Y. Bone versus immune system. Nature. 2000;408(6812):535-536. DOI: 10.1038/35046196.
2. Michael H., Härkönen P.L., Väänänen H.K., Hentunen T.A. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res. 2005;20(12):2224-2232. DOI: 10.1359/JBMR.050803.
3. Pacifici R. The immune system and bone. Arch Biochem Biophys. 2010;503(1):41-53. DOI: 10.1016/j.abb.2010.05.027.
4. Nakashima T., Takayanagi H. Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol. 2009;29(5):555-567. DOI: 10.1007/s10875-009-9316-6.
5. Breuil V., Ticchioni M., Testa J., Roux C.H., Ferrari P., Breittmayer J.P., Albert-Sabonnadière C., Durant J., et al. Immune changes in post-menopausal osteoporosis: the Immunos study. Osteoporos Int. 2010;21(5):805-814. DOI: 10.1007/s00198-009-1018-7.
6. Dolzhikov A.A., Shevchenko O.A. Stimulation of proliferation and osteoblastic differentiation of osteogenic precursors as pharmacological effects of resveratrol in hypoestrogenism-induced osteoporosis: structural and functional manifestations and possible mechanisms. Humans and their health. 2024;27(3):109-118 (in Russ.). DOI: 10.21626/vestnik/2024-3/12. EDN: XMAUWW
7. Yousefzadeh N., Kashfi K., Jeddi S., Ghasemi A. Ovariectomized rat model of osteoporosis: a practical guide. EXCLI J. 2020;19:89-107. DOI: 10.17179/excli2019-1990.
8. Dolzhikov A.A., Shevchenko O.A.,Dolzhikova I.N. Dynamics of structural and functional changes in the proximal epiphysis of the femur in experimental postmenopausal osteoporosis and resveratrol therapy. Modern Science. 2024;(7-1):42-50 (in Russ.). EDN: MMYALY
9. Majljan Je.A., Kamsadze I.G., Besedina E.I., Kosteckaja N.I., Zjablicev D.V., Kolesnichenko D.A., Vorozhko A.A., Mezhova O.K., et al. The role of estrogens in the regulation of immune factors involved in the postmenopausal osteoporosis pathogenesis (literature review). Medikosocial'nye problemy sem'i. 2021;26(3):124-130 (in Russ.). EDN: WWXGBC.
10. Povoroznjuk V.V., Reznichenko N.A., Majljan Je.A. Immunologic aspects of postmenopausal osteoporosis. Bol'. Sustavy. Pozvonochnik. 2013;(3):21-26 (in Russ.). DOI: 10.22141/2224-1507.3.11.2013.82325. EDN: RSAQBR.
11. Kosyreva A.M., Makarova O.V. Sex differences in morphofunctional changes in the immune system in Wistar rats of different age groups with experimental endotoxinemia. Kursk Scientific and Practical Bulletin “Man and His Health”. 2020;2:65-73 (in Russ.). DOI: 10.21626/vestnik/2020-2/09. EDN: RYQYDO.
12. Roggia C., Gao Y., Cenci S., Weitzmann M.N., Toraldo G., Isaia G., Pacifici R. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A. 2001;98(24): 13960-13965. DOI: 10.1073/pnas.251534698.
13. Cenci S., Weitzmann M.N., Roggia C., Namba N., Novack D., Woodring J., Pacifici R. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest. 2000;106(10):1229-1237. DOI: 10.1172/JCI11066.
14. Rogers A., Eastell R. The effect of 17beta-estradiol on production of cytokines in cultures of peripheral blood. Bone. 2001;29(1):30-34. DOI: 10.1016/s8756-3282(01)00468-9.
15. Wei S., Kitaura H., Zhou P., Ross F.P., Teitelbaum S.L. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest. 2005;115(2):282-290. DOI: 10.1172/JCI23394.
16. Charatcharoenwitthaya N., Khosla S., Atkinson E.J., McCready L.K., Riggs B.L. Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res. 2007;22(5):724-729. DOI: 10.1359/jbmr.070207.
17. Zheng S.X., Vrindts Y., Lopez M., De Groote D., Zangerle P.F., Collette J., Franchimont N., Geenen V., et al. Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas. 1997;26(1):63-71. DOI: 10.1016/s0378-5122(96)01080-8.
18. Giuliani N., Colla S., Sala R., Moroni M., Lazzaretti M., La Monica S., Bonomini S., Hojden M., et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood. 2002;100(13):4615-4621. DOI: 10.1182/blood-2002-04-1121.
19. Ryan M.R., Shepherd R., Leavey J.K., Gao Y., Grassi F., Schnell F.J., Qian W.P., Kersh G.J., et al. An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc Natl Acad Sci U S A. 2005;102(46):16735-16740. DOI: 10.1073/pnas.0505168102.
20. Ibáñez L., Rouleau M., Wakkach A., Blin-Wakkach C. Gut microbiome and bone. Joint Bone Spine. 2019;86(1):43-47. DOI: 10.1016/j.jbspin.2018.02.008.
21. Tyagi A.M., Srivastava K., Mansoori M.N., Trivedi R., Chattopadhyay N., Singh D. Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS One. 2012;7(9):e44552. DOI: 10.1371/journal.pone.0044552.
22. Adeel S., Singh K., Vydareny K.H., Kumari M., Shah E., Weitzmann M.N., Tangpricha V. Bone loss in surgically ovariectomized premenopausal women is associated with T lymphocyte activation and thymic hypertrophy. J Investig Med. 2013;61(8):1178-1183. DOI: 10.2310/JIM.0000000000000016.
23. Tella S.H., Gallagher J.C. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155-170. DOI: 10.1016/j.jsbmb.2013.09.008.
24. Michael H., Härkönen P.L., Väänänen H.K., Hentunen T.A. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res. 2005;20(12):2224-2232. DOI: 10.1359/JBMR.050803.
25. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7(4):292-304. DOI: 10.1038/nri2062.
26. Miyaura C., Onoe Y., Kusano K., Ohta H., Nozawa S., Suda T. Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. J Clin Invest. 1994;94(3):1090-1097. DOI: 10.1172/JCI117424.
27. Onoe Y., Miyaura C., Ito M., Ohta H., Nozawa S., Suda T.Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice. J Bone Miner Res. 2000;15(3):541-549. DOI: 10.1359/jbmr.2000.15.3.541.
28. Miyaura C., Onoe Y., Inada M., Maki K., Ikuta K., Ito M., Suda T. Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency. Proc Natl Acad Sci U S A. 1997;94(17):9360-9365. DOI: 10.1073/pnas.94.17.9360.
29. Gao X., Xu Y.X., Janakiraman N., Chapman R.A., Gautam S.C. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem Pharmacol. 2001;62(9):1299-1308. DOI: 10.1016/s0006-2952(01)00775-4.
30. Sharma S., Chopra K., Kulkarni S.K., Agrewala J.N. Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin Exp Immunol. 2007;147(1):155-163. DOI: 10.1111/j.1365-2249.2006.03257.x.
31. Borsuk O.S., Masnaja N.V., Sherstoboev E.Ju., Isajkina N.V., Kalinkina G.I.Comparative characteristics of the effect of polyphenolic and polysaccharide compounds isolated from plants of Siberia and the Far East on the immune system.Russian journal of allergy. 2011;(S4-1):60-61 (in Russ.). EDN: UPUEAF.
32. Shukshina Ju.G., Massnaja N.V., Isajkina I.V., Sherstoboev E.Ju., Kalinkina G.I. Influence of vegetative polyphenolic complexes on the functional activity of immunocompetent cells in vitro. Immunologija. 2014;35(3):138-142 (in Russ.). EDN: SJUZON.
33. Dolgikh O.V., Dianova D.G., Shirinkina A.S., Bombela T.V. Immunomodulatory properties of plant polyphenols shown in an in vitro experimental model. Meditsinskaya immunologiya. 2024;26(1):143-150 (in Russ.). DOI: 10.15789/1563-0625-IPO-2655. EDN: FQZKEP.
34. Yahfoufi N., Alsadi N., Jambi M., Matar C. The Immunomodulatory and Anti-Inflammatory Role of Polyphenols. Nutrients. 2018;10(11):1618. DOI: 10.3390/nu10111618.
35. Malaguarnera L. Influence of Resveratrol on the Immune Response. Nutrients. 2019;11(5):946. DOI: 10.3390/nu11050946.
36. Tyagi A.M., Srivastava K., Sharan K., Yadav D., Maurya R., Singh D. Daidzein prevents the increase in CD4+CD28null T cells and B lymphopoesis in ovariectomized mice: a key mechanism for anti-osteoclastogenic effect. PLoS One. 2011;6(6):e21216. DOI: 10.1371/journal.pone.0021216.
Review
For citations:
Dolzhikov A.A., Shevchenko O.A. Morphological manifestations of the immunomodulatory effect of resveratrol in postmenopausal osteoporosis. Humans and their health. 2025;28(4):94-106. (In Russ.) EDN: PSCAGP
Views:
71
JATS XML
Email this article 